A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)
Cristina Mussini(University of Modena and Reggio Emilia), Franco Maggiolo(Ospedale Papa Giovanni XXIII), Enrica Roncaglia(University of Modena and Reggio Emilia), Gabriella d’Ettorre(Policlinico Umberto I), Andrea Antinori(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Anna Maria Cattelan(University of Padua), Emanuele Focà(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Enrico Barchi(Santa Maria Nuova Hospital), Stefano Rusconi(University of Milan), Vanni Borghi(University of Modena and Reggio Emilia), Silvia Nozza(IRCCS Ospedale San Raffaele), Paolo Bonfanti(University of California San Diego), Daniela Segala(Ospedale Sant'Anna), Stefano Bonora(Ospedale Amedeo di Savoia), Anna Degli Antoni(Ospedale di Parma), Silvia Limonta(University of Milan), Daniela Francisci(University of Perugia), Antonio Di Biagio
Cited by 16
Related Papers
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
|Nature Communications|2020|846
Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
|New England Journal of Medicine|1992|685